Session » Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 543

Adverse Events in Rheumatoid Arthritis Patients Treated with Disease Modifying Biological Drugs at Hospital Docente Padre Billini in Santo Domingo

9:00AM-11:00AM: Abstract Number: 499

Assessment of Early Improvement in Pain and Other ACR Components As Predictors for Achieving Low Disease Activity or Remission in Three Phase 3 Trials of RA Patients Treated with Baricitinib

9:00AM-11:00AM: Abstract Number: 533

Assessment of Radiographic Progression in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years

9:00AM-11:00AM: Abstract Number: 510

Association between Clinical Response and Normalization of Patient-Reported Outcome Measures in Rheumatoid Arthritis: Post-Hoc Analysis from Two Phase 2b Filgotinib Studies

9:00AM-11:00AM: Abstract Number: 540

Being Elderly Is Not a Predictive Factor of Discontinuation of Abatacept Due to Adverse Events in Rheumatoid Arthritis Patients with Concomitant Methotrexate: A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study

9:00AM-11:00AM: Abstract Number: 503

BMS-986195 Is a Highly Selective and Rapidly Acting Covalent Inhibitor of Bruton’s Tyrosine Kinase with Robust Efficacy at Low Doses in Preclinical Models of RA and Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 514

BMS-986195, a Novel, Rapidly Acting, Covalent Inhibitor of Bruton’s Tyrosine Kinase: Safety, Pharmacokinetic and Pharmacodynamic Profiles in Healthy Participants

9:00AM-11:00AM: Abstract Number: 527

Cardiovascular Safety of Tocilizumab Versus Abatacept in Patients with Rheumatoid Arthritis: A Multi-Database Study

9:00AM-11:00AM: Abstract Number: 520

Clinical and Structural Responses of Patients with Active Rheumatoid Arthritis (RA) Using Step-up Dosing of Tofacitinib in a Treat to Target Approach

9:00AM-11:00AM: Abstract Number: 531

Comparative Effectiveness of Tofacitinib Versus Baricitinib in Rheumatoid Arthritis Using a Systematic Review and Network Meta-Analysis of Randomized Trials

9:00AM-11:00AM: Abstract Number: 526

Comparative Pulmonary Safety of Abatacept and Tumor Necrosis Factor Inhibitors in Patients with RA and Chronic Pulmonary Condition

9:00AM-11:00AM: Abstract Number: 551

Comparison of Drug Tolerability and Discontinuation Reasons between 7 Biologics in Patients with Rheumatoid Arthritis -Results from Kansai Consortium for Well-Being of Rheumatic Disease Patients (ANSWER cohort)-

9:00AM-11:00AM: Abstract Number: 539

Comparison of Oral Versus Parenteral Methotrexate in Rheumatoid Arthritis: A Meta-Analysis

9:00AM-11:00AM: Abstract Number: 546

Concomitant Hydroxychloroquine Impact on Anti-TNF Persistence in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 541

Decreasing Trend of Serious Infections Incidence Rate Along Years in Rheumatoid Arthritis Patients Exposed to Biologics. Data from Two Latin America Registries

9:00AM-11:00AM: Abstract Number: 535

Effect of a Step-up or Step-Down in Tofacitinib Dose on Efficacy and Safety in Long-Term Extension Studies

9:00AM-11:00AM: Abstract Number: 534

Effect of Baseline MTX Dose on Clinical Efficacy and Safety in Rheumatoid Arthritis Patients Treated with Filgotinib: Post-Hoc Analysis from a Phase 2B Study

9:00AM-11:00AM: Abstract Number: 536

Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen Cohort

9:00AM-11:00AM: Abstract Number: 530

Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 516

Efficacy of Adding Iguratimod Therapy in Rheumatoid Arthritis　Patients Who Had Inadequate Response to Biologic Dmards

9:00AM-11:00AM: Abstract Number: 495

Efficacy of Tofacitinib in Patients with Moderate to Severe Rheumatoid Arthritis By Baseline C-Reactive Protein Levels and Erythrocyte Sedimentation Rates

9:00AM-11:00AM: Abstract Number: 512

Efficacy Response to Baricitinib Based on Baseline Characteristics in Patients Who Are Inadequate Responders to Conventional DMARD

9:00AM-11:00AM: Abstract Number: 525

Efficacy, Tolerability and Reasons for Changing Dmards, Biologics and Small Molecule Drugs in RA Patients without RA Lung Disease from a United States Tertiary Referral Center

9:00AM-11:00AM: Abstract Number: 517

Evaluation of the Effectiveness of Injectable Methotrexate for the Treatment of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 505

Exposure-Response Analyses of the Effect of Upadacitinib on ACR Responses in the Phase 2b Rheumatoid Arthritis Trials in Patients with Inadequate Response to Methotrexate or to Anti-Tumor Necrosis Factor Therapy

9:00AM-11:00AM: Abstract Number: 519

Filgotinib, a Selective Janus Kinase 1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects

9:00AM-11:00AM: Abstract Number: 532

Genetic Predictors of Iguratimod Clinical Response and Toxicity in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 528

Impact of Comorbidities on the Occurrence of Infections in Rheumatoid Arthritis Treated By Biologic Agents

9:00AM-11:00AM: Abstract Number: 508

Improved Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Failed Adalimumab or Placebo Treatment and Were Rescued with Baricitinib

9:00AM-11:00AM: Abstract Number: 545

Incidence of Infusion Reactions to Intravenous Golimumab: Results from a Prospective, Real-World Community Registry

9:00AM-11:00AM: Abstract Number: 549

Increases in Lipid Levels Following Sirukumab Treatment Are Associated with Suppression of Inflammation in Rheumatoid Arthritis: Results from Two Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 542

Is There Any Difference in RA Patients for Methotrexate Use Vs. Leflunomide Use As a Concomitant Treatment with Biological and Targeted Synthetic Dmards in Turkbio Registry?

9:00AM-11:00AM: Abstract Number: 548

LDL and HDL Changes with Sirukumab Treatment Are Anti-Atherogenic: Results from Two Phase 3 Trials in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 515

Leukopenia and Tumor Necrosis Factor Alpha Inhibitor Therapy

9:00AM-11:00AM: Abstract Number: 547

Long-Term Risk of Serious Infections in Patients with Rheumatoid Arthritis Treated with Rituximab: 5 Year Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 509

Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study

9:00AM-11:00AM: Abstract Number: 550

Long-Term Safety of Tocilizumab from Large Clinical Trial and Postmarketing Populations

9:00AM-11:00AM: Abstract Number: 500

Low Patient Global Assessment Scores in Rheumatoid Arthritis Are Associated with Pain and Physical Function in Patients Treated with Tofacitinib: A Post-Hoc Analysis of Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 504

Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease-Related Biomarkers in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 537

No Effect of Baseline Serum CRP Levels on Clinical Efficacy Parameters in Rheumatoid Arthritis Patients Treated with Filgotinib: Post Hoc Analysis from Two Phase 2B Studies

9:00AM-11:00AM: Abstract Number: 501

Patient-Reported Outcomes of Long-Term Upadacitinib Use in Patients with Rheumatoid Arthritis: Interim Analysis Results of a Phase 2, Open-Label Extension Study

9:00AM-11:00AM: Abstract Number: 524

Predictors of Mortality in RA Patients before Biologic Therapy

9:00AM-11:00AM: Abstract Number: 523

Prevalence of Occult Hepatitis B Carrier Status and Its Associated Risk Factors in Patients with Rheumatic Diseases Undergoing Biological Therapies

9:00AM-11:00AM: Abstract Number: 529

Pulmonary Involvement in Our Patients with Rheumatoid Arthritis Under Biological Therapy: A Tertiary Hospital Experience

9:00AM-11:00AM: Abstract Number: 502

Reduction in Disease Activity in Patients with RA and an Inadequate Response to MTX: Baricitinib Compared to Adalimumab and Placebo

9:00AM-11:00AM: Abstract Number: 496

Repeated Rituximab Infusions for the Therapy of Rheumatoid Arthritis Is Not Associated with Increased Rates of Serious Infections

9:00AM-11:00AM: Abstract Number: 498

Response to Abatacept of Different Patterns of Interstitial Lung Disease in Rheumatoid Arthritis. Multicenter Study of 63 Patients

9:00AM-11:00AM: Abstract Number: 511

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis

9:00AM-11:00AM: Abstract Number: 544

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06650833, a Novel, Potentially First-in-Class Inhibitor of Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) in Healthy Subjects

9:00AM-11:00AM: Abstract Number: 538

Severe Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 497

The JAK1 Selective Inhibitor Filgotinib Regulates Both Enthesis and Colon Inflammation in a Mouse Model of Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 518

The Occurrence of Shingles and the Effect of Zoster Vaccination with the Use of Methotrexate in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 506

The Selective JAK1 Inhibitor Upadacitinib Has No Effect on Pharmacokinetics of the Hormonal Contraceptives Levonorgestrel and Ethinylestradiol

9:00AM-11:00AM: Abstract Number: 513

Time to Achieve Moderate/Low Disease Activity and Remission in RA Patients on Baricitinib Compared to Adalimumab, Methotrexate, and Placebo

9:00AM-11:00AM: Abstract Number: 507

Tofacitinib Monotherapy Improves Left Ventricular Mass and Cardiac Output in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 522

Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years

9:00AM-11:00AM: Abstract Number: 521

Update on the Clinical Phase 1 and Phase 2 Trials Investigating the Fully Human Immunocytokine Dekavil (F8IL10) in Patients with Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].